# Kiniksa Pharmaceuticals International, plc (KNSA) insider trading

> In the 12 months to Nov 4, 2026, 8 KNSA insiders reported open-market sales of $110.6M across 29 filings; no open-market purchases were filed.

Canonical: https://massive.com/quote/knsa/insider-trading
Latest filing: 2026-11-03 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $110.6M | 29 filings · 8 insiders |
| Open-market purchases | $0 | 0 filings |
| Pre-arranged sales (10b5-1) | 28 of 29 | $110.3M of $110.6M sold (100%) |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| Sanj K. Patel | CHAIRMAN & CEO | $66.8M | — | 4 | 100% of sales | 2026-11-03 |
| John F. Paolini | CHIEF MEDICAL OFFICER | $16.9M | — | 4 | 100% of sales | 2026-11-03 |
| Ross Moat | CHIEF OPERATING OFFICER | $9.8M | — | 3 | 100% of sales | 2026-11-03 |
| Mark Ragosa | CHIEF FINANCIAL OFFICER | $8.9M | — | 6 | 100% of sales | 2026-11-03 |
| Michael R. Megna | CHIEF ACCOUNTING OFFICER | $4.1M | — | 3 | 100% of sales | 2026-11-03 |
| Barry D. Quart | Director | $2.7M | — | 5 | 100% of sales | 2026-04-29 |
| Eben Tessari | CHIEF OPERATING OFFICER | $1.0M | — | 3 | 100% of sales | 2025-12-17 |
| G. Bradley Cole | Director | $299.1K | — | 1 | — | 2026-07-31 |

## Open-market trades by filing

29 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-11-03 | 2026-10-30 | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale (10b5-1) | 36,260 ordinary shares | $3.4M | 18,047 | — |
| 2026-11-03 | 2026-10-30 | Sanj K. Patel | CHAIRMAN & CEO | Sale (10b5-1) | 402,494 ordinary shares | $37.4M | 784,621 | — |
| 2026-11-03 | 2026-10-30 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale (10b5-1) | 96,000 ordinary shares | $8.9M | 69,922 | — |
| 2026-11-03 | 2026-11-02 | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale (10b5-1) | 36,783 ordinary shares | $3.4M | 43,610 | — |
| 2026-11-03 | 2026-10-30 | Ross Moat | CHIEF OPERATING OFFICER | Sale (10b5-1) | 103,585 ordinary shares | $9.6M | 22,658 | — |
| 2026-09-03 | 2026-09-03 | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale (10b5-1) | 4,600 ordinary shares | $369.4K | 29,062 | — |
| 2026-07-31 | 2026-07-29 | G. Bradley Cole | Director | Sale | 3,673 ordinary shares | $299.1K | 11,672 | — |
| 2026-05-05 | 2026-05-01 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale (10b5-1) | 58,424 ordinary shares | $3.1M | 86,720 | — |
| 2026-05-01 | 2026-05-01 | Sanj K. Patel | CHAIRMAN & CEO | Sale (10b5-1) | 48,565 ordinary shares | $2.6M | 0 | — |
| 2026-04-30 | 2026-04-28 | Sanj K. Patel | CHAIRMAN & CEO | Sale (10b5-1) | 508,339 ordinary shares | $26.4M | 0 | — |
| 2026-04-29 | 2026-04-28 | Barry D. Quart | Director | Sale (10b5-1) | 13,099 ordinary shares | $656.3K | 12,546 | — |
| 2026-04-13 | 2026-04-09 | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale (10b5-1) | 6,625 ordinary shares | $309.3K | 27,418 | — |
| 2026-04-13 | 2026-04-09 | Ross Moat | CHIEF OPERATING OFFICER | Sale (10b5-1) | 1,703 ordinary shares | $79.5K | 12,029 | — |
| 2026-04-08 | 2026-04-06 | Barry D. Quart | Director | Sale (10b5-1) | 6,901 ordinary shares | $345.1K | 12,546 | — |
| 2026-04-08 | 2026-04-06 | Sanj K. Patel | CHAIRMAN & CEO | Sale (10b5-1) | 7,278 ordinary shares | $364.0K | 0 | — |
| 2026-04-08 | 2026-04-06 | Ross Moat | CHIEF OPERATING OFFICER | Sale (10b5-1) | 2,367 ordinary shares | $115.0K | 12,029 | — |
| 2026-03-11 | 2026-03-09 | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale (10b5-1) | 36,722 ordinary shares | $1.7M | 12,086 | — |
| 2026-03-04 | 2026-03-02 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale (10b5-1) | 40,000 ordinary shares | $1.8M | 67,038 | — |
| 2026-02-12 | 2026-02-10 | Barry D. Quart | Director | Sale (10b5-1) | 2,800 ordinary shares | $126.0K | 12,546 | — |
| 2026-02-11 | 2026-02-09 | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale (10b5-1) | 17,845 ordinary shares | $772.3K | 20,817 | — |
| 2026-02-04 | 2026-02-02 | Barry D. Quart | Director | Sale (10b5-1) | 15,960 ordinary shares | $721.6K | 12,546 | — |
| 2026-01-09 | 2026-01-08 | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale (10b5-1) | 12,000 ordinary shares | $502.7K | 19,086 | — |
| 2025-12-17 | 2025-12-15 | Barry D. Quart | Director | Sale (10b5-1) | 20,129 ordinary shares | $835.6K | 12,546 | — |
| 2025-12-17 | 2025-12-15 | Eben Tessari | CHIEF OPERATING OFFICER | Sale (10b5-1) | 12,048 ordinary shares | $500.7K | 16,666 | — |
| 2025-12-10 | 2025-12-08 | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale (10b5-1) | 42,841 ordinary shares | $1.8M | 31,086 | — |
| 2025-12-01 | 2025-11-26 | Eben Tessari | CHIEF OPERATING OFFICER | Sale (10b5-1) | 200 ordinary shares | $8.6K | 22,714 | — |
| 2025-11-19 | 2025-11-17 | Eben Tessari | CHIEF OPERATING OFFICER | Sale (10b5-1) | 12,470 ordinary shares | $514.2K | 34,539 | — |
| 2025-11-14 | 2025-11-12 | Mark Ragosa | CHIEF FINANCIAL OFFICER | Sale (10b5-1) | 19,900 ordinary shares | $814.7K | 31,086 | — |
| 2025-11-04 | 2025-10-31 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale (10b5-1) | 82,542 ordinary shares | $3.1M | 61,324 | — |

## Other insider activity (not market trades)

- Option exercises: 100 records
- Tax withholding: 18 records
- Grants and awards: 6 records
- Gifts: 6 records
- Other: 1 record

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Pre-arranged (10b5-1)**: The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

## FAQ

### Has Kiniksa Pharmaceuticals International, plc's CEO sold stock?

Yes. Sanj K. Patel (CEO) sold 966,676 shares ($66.8M) between Apr 2026 and Nov 2026, all under a pre-arranged 10b5-1 plan.

### How current is KNSA’s insider data?

These are KNSA Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The KNSA Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=KNSA&filing_date.gte=2025-11-04&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Kiniksa Pharmaceuticals International, plc (KNSA) stock price](https://massive.com/quote/knsa.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms